Davis ID, et al. - Given the association of enzalutamide, an androgen-receptor inhibitor, with improved overall survival in men with castration-resistant prostate cancer, researchers examined if the addition of enzalutamide to testosterone suppression, with or without early docetaxel, could improve survival in men with metastatic, hormone-sensitive prostate cancer. A total of 1,125 men were assigned to receive testosterone suppression plus either open-label enzalutamide or a standard nonsteroidal antiandrogen therapy (standard-care group) in this open-label, randomized, phase 3 trial. As per outcomes, men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression display significantly longer progression-free and overall survival in correlation with enzalutamide vs standard care. They noted a higher incidence of seizures and other toxic effects in the enzalutamide group, especially among those treated with early docetaxel.